# scientific reports

Check for updates

## **The SIRT2‑AMPK axis regulates OPEN autophagy induced by acute liver failure**

**Qingqi Zhang, JinGuo, Chunxia Shi, Danmei Zhang, Yukun Wang, LuwenWang  & Zuojiong Gong** 

**This study explores the role of SIRT2 in regulating autophagy and its interaction with AMPK in the context of acute liver failure (ALF). This study investigated the efects of SIRT2 and AMPK on autophagy in ALF mice and TAA-induced AML12 cells. The results revealed that the liver tissue in ALF model group had a lot of infammatory cell infltration and hepatocytes necrosis, which were reduced by SIRT2 inhibitor AGK2. In comparison to normal group, the level of SIRT2, P62, MDA, TOS in TAA group were signifcantly increased, which were decreased in AGK2 treatment. Compared with normal group, the expression of P-PRKAA1, Becilin1 and LC3B-II was decreased in TAA group. However, AGK2 enhanced the expression of P-PRKAA1, Becilin1 and LC3B-II in model group. Overexpression of SIRT2 in AML12 cell resulted in decreased P-PRKAA1, Becilin1 and LC3B-II level, enhanced the level of SIRT2, P62, MDA, TOS. Overexpression of PRKAA1 in AML12 cell resulted in decreased SIRT2, TOS and MDA level and triggered more autophagy. In conclusion, the data suggested the link between AMPK and SIRT2, and reveals the important role of AMPK and SIRT2 in autophagy on acute liver failure.**

Acute liver failure (ALF) is a critical clinical condition marked by rapid hepatocyte function deterioration in individuals without prior liver disease. It can result from various factors, including prolonged ischemia, toxic exposure, drug reactions (both idiosyncratic and dose-dependent), tumors, metabolic disorders, as well as infectious and immune-mediated processes<sup>1</sup>. Currently, effective treatments for ALF are limited.. Autophagy, a lysosome-mediated degradation process, is essential for cellular and metabolic balance in the live[r2](#page-10-1) . It is intricately linked to various liver diseases, such as drug-induced liver injury (DILI) $^3$  $^3$ , viral hepatitis $^4$  $^4$ , and non-alcoholic fatty liver disease<sup>[5](#page-10-4)</sup>, all of which are associated with autophagy impairment.

Autophagy involves sophisticated molecular pathways that transport intracellular components to lysosomes for breakdown and reuse, crucial for maintaining cellular and organismal homeostasis. Molecular pathways central to the maintenance of cellular and organismal homeostasis by autophagy<sup>6</sup>. In mammalian cells, autophagy initiation requires the activation of UNC-52-like kinase 1 (ULK1) or ULK2 at the phagophore assembly site (PAS). AMP-activated protein kinase (AMPK), a sensor of intracellular ATP levels, comprises a catalytic subunit (PRKAA/AMPKα) and two regulatory subunits (PRKAB/AMPKβ and PRKAG/AMPKγ), the α-subunit contains a catalytic kinase domain and exists as either the α1 or α2 isoform[7](#page-10-6) . When energy is low, AMPK activates and phosphorylates ULK1 to promote autophagy<sup>8</sup>. Beclin1, part of the class III phosphoinositide 3-kinase (PtdIns3K) complexes, also facilitates autophagy<sup>9</sup>. Notably, acetaminophen (APAP) overdose induces autophagy, and its pharmacological activation can prevent APAP-induced liver injury<sup>[10](#page-10-9)</sup>. Lipocalin prevents APAP-induced hepatotoxicity by activating AMPK and ULK1-mediated autophagy<sup>11</sup>. Numerous studies have demonstrated a close link between PRKAA1 and autophagy<sup>12[,13](#page-10-12)</sup>. In present study, we would like to explore the expression of PRKAA1 in ALF, as well as to study the link between PRKAA1 and SIRT2.

Sirtuin 2 (SIRT2), a NAD + -dependent deacetylase, predominantly resides in the cytoplasm but also exists in mitochondria and the nucleus<sup>14</sup>. Recent studies highlight its significant role in various liver diseases, including hepatocellular carcinoma<sup>15</sup>, alcoholic liver disease<sup>16</sup>, and non-alcoholic fatty liver disease17. Tang et al. demonstrated that SIRT2 binds to liver kinase B1 (LKB1), deacetylating it at lysine 48, thereby enhancing LKB1 phosphorylation and the subsequent LKB1-AMPK signaling activation<sup>18</sup>. Moreover, SIRT2 also impedes cardiac hypertrophy through LKB1 deacetylation and the activation of LKB1-AMPK signaling<sup>19</sup>. SIRT2 may achieve regulation of autophagy by modulating the LKB1-AMPK axis. SIRT2 appears to play diferent roles in acute and chronic diseases. In the mice model of cisplatin-induced acute kidney injury, SIRT2 knockout mice showed improvements in apoptosis, necrosis, and inflammation<sup>20</sup>. In acute liver failure, the pathways by which

Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China. <sup>[2]</sup> email: zjgong@163.com

SIRT2 regulates autophagy are unknown. Our previous study has verifed that SIRT2 inhibitor AGK2 possesses hepatoprotective properties via regulating the MFN2-PERK axis and ferroptosis signaling pathway<sup>[21](#page-10-19)</sup>. Here, we aimed to explore how SIRT2 infuences autophagy in AML12 cells and mice with TAA-induced ALF, focusing particularly on its interaction with AMPK.

#### **Materials and methods Reagents and antibodies**

We sourced AGK2 from Selleckchem (USA) and thioacetamide (TAA) from Sigma (St. Louis, USA). Plasmids including pLV3-CMV-PRKAA1-Puro, pLV3-CMV-SIRT2-Puro, pLV3-U6-PRKAA1-shRNA-Puro, and pLV3- U6-SIRT21-shRNA-Puro were acquired from Miaoling Biology (Wuhan, China). The pCMV-mCherry-GFP-LC3B plasmid was obtained from Beyotime Institute of Biotechnology (Wuhan, China). Hief Trans® Liposomal Transfection Reagent was purchased from Yeasen Biotechnology (Shanghai, China). Antibodies targeting SIRT2, PRKAA1/AMPKα1, P-AMPKα1, LC3B, P62, Beclin1, and GAPDH were procured from Abcam (Cambridge, MA, USA). Dulbecco's Modifed Eagle Medium (DMEM) and Fetal Bovine Serum (FBS) were from Gibco (NY, USA). The Malondialdehyde (MDA) assay kit came from Naijing Jiancheng Bioengineering Institute (Naijing, China), and Total Oxidant Status (TOS) kits were sourced from Elabscience (Wuhan, China).

#### **Animals**

Male C57BL/6 wild-type mice  $(n=30)$  specific pathogen-free (SPF)  $(20-25 g)$  were purchased from Experimental Animal Center of Wuhan University. Protocols of this study were approved and consented on by the Ethics Committee of Renmin Hospital of Wuhan University. The mice were fed in the animal experiment center in Renmin Hospital of Wuhan University. They were acclimated for 1 week before modeling. 30 mice were divided randomly into 3 group: normal  $(n=10)$ , model  $(n=10)$ , AGK2 group  $(n=10)$ . The sample size of mice was obtained by referring to other acute liver failure literatures<sup>22–25</sup>. The AGK2 (1 µmol/mouse) was injected into abdominal cavities in mice in AGK2 group. The same volume of normal saline was given in normal group mice. Afer 2 h, mice in the model group and AGK2 group were induced by intraperitoneal injection of TAA (600 mg/kg). The doses of TAA were administrated according to previous studies<sup>[26,](#page-10-22)27</sup>. All experimental mice were sacrifced under anesthesia afer 24 h when TAA administration. All animals received care in accordance with the recommendations of the National Institutes of Health Guide for Care and Use of Laboratory Animals and adhered to the ARRIVE guidelines.

### **Cell culture and transfection**

The mouse liver cell line AML12 obtained from China Center for Type Culture Collection (CCTCC) were grown in Dulbecco's Modifed Eagle's Medium (DMEM) medium containing 10% fetal bovine serum (FBS), incubated at 37℃ in a 5% CO2 atmosphere. First, Diferent TAA concentrations (0 mM, 30 mM, 60 mM, 90 mM, 120 mM, 150 mM) were used to stimulate AML12 cells to detect the cell death rate and select the appropriate concentration of TAA for ALF modeling in vitro experiment. Ten cells were categorized into normal, TAA, and TAA+AGK2 groups. Excluding the normal group, TAA (90 mM) was added to the media of each group for 24 h. In the TAA + AGK2 group, AGK2 (1  $\mu$ M) was introduced to the medium 2 h prior to TAA (90 mM) addition.

#### **The cell death rate of AML12 cells was measured**

The cell death rate of AML12 cells was determinated by a kit (BD, USA). The dosage of TAA (0 mM, 30 mM, 60 mM, 90 mM, 120 mM, 150 mM) was given to each well of a 6-well plate. Cells were collected afer 24 h when TAA administration. Ten the cells were washed twice, added with 5 μL PE Annexin V and 5 µl 7-AAD, and gently vortexed and incubated. Finally, add 400  $\mu$ l of 1  $\times$ Binding Buffer and the cell death rate was measured by flow cytometry (BD, USA).

#### **Lentiviral vectors transduction for SIRT2 and PRKAA1 knockdown**

Plasmids pLV3-U6-PRKAA1-shRNA-Puro (sh PRKAA1) and pLV3-U6-SIRT21-shRNA-Puro (sh SIRT2), along with an empty vector (LKO), were transfected into 293 T producer cells using Hieff Trans® Liposomal Transfection Reagent, following the manufacturer's protocol. Afer 48 h of culture, supernatants were collected and concentrated via ultracentrifugation. The packaged sh PRKAA1, sh SIRT2, and LKO were then transfected into AML12 cells. Transfectants underwent selection with puromycin, and the efficiency of SIRT2 and PRKAA1 knockdown was verifed by western blot analysis.

#### **Lentiviral vector transfection for SIRT2 and PRKAA1 overexpression**

We utilized pLV3-CMV-PRKAA1-Puro (OE PRKAA1) and pLV3-CMV-SIRT2-Puro (OE SIRT2), along with an empty vector (CMV) for transfection. These were transfected into 293 T producer cells alongside packaging vectors. The transfection procedure followed is the same as described in Sect. 2.4.

#### **Histopathological analysis and biochemical examination**

For histopathological analysis, a portion of the fresh liver specimens from mice was fxed in 10% neutral-bufered formalin, embedded in paraffin, sectioned, and stained with hematoxylin–eosin (HE). These sections were then examined under a BX 51 light microscope (Olympus, Japan). Another portion of the liver specimens was fxed in 4% glutaraldehyde, dehydrated with ethanol and acetone, embedded in epoxy resin, sectioned, and stained with saturated uranium acetate and lead citrate for ultrastructural observation under a transmission electron microscope (HITACHI HT7700, Japan). Serum alanine aminotransferase (ALT) and aspartate aminotransferase

2

(AST) levels in each group were measured using an automated Aeroset chemistry analyzer (Abbott Co. Ltd.,  $IISA$ ).

#### **Western blotting**

Proteins (30 μg) extracted from the cells were separated on 12% SDS-PAGE and transferred onto polyvinylidene fuoride (PVDF) membranes. Considering proteins with similar molecular weight sizes, membranes were then cut according to the sizes of proteins to ensure that all PVDF bands were transferred and tested in the same Wb experiment. Afer blocking with 20% non-fat milk for 1 h, the membranes were incubated overnight at 4 °C with primary antibodies against P-AMPKα1 (1:1000), P62 (1:10,000), LC3B (1:2000), Beclin1 (1:1000), and GAPDH (1:2000). Subsequently, they were incubated with HRP-conjugated Affinipure Goat Anti-Rabbit IgG( $H + L$ ) (1:5000) for 1 h. Protein bands were visualized and quantifed using QuickChemi 5200.

#### **Immunofuorescence assay**

Cells subjected to specifc treatments were fxed with 4% paraformaldehyde for 30 min and permeabilized with 0.5% Triton X-100 for 15 min. Afer washing with ice-cold phosphate-bufered saline (PBS) and blocking with 0.5% bovine serum albumin (BSA) in PBS for 30 min, cells were incubated with rabbit polyclonal antibodies against SIRT2, PRKKA1, and P-PRKKA1, followed by treatment with TRITC-conjugated goat anti-rabbit IgG antibody. Nuclei were stained with DAPI. Te cells were then visualized using a fuorescence microscope (Olympus, Japan, #BX53).

#### **pCMV‑mCherry‑GFP‑LC3B assay**

pCMV-mCherry-GFP-LC3B plasmid is ofen transfected into cells to analysis the autophagy level. GFP puncta were used a confocal microscopy (Olympus, Japan, #FV1200).

#### **Detection of MDA and TOS**

The MDA and TOS kits were performed according to the corresponding manufacturer's instructions. The values for the levels of MDA and TOS in the AML12 cells and liver tissue were detected with the multimode plate reader.

#### **Statistical analysis**

Statistical analysis and graph generation were performed using GraphPad Prism 9.5. Data normality was assessed using the Shapiro–Wilk test, and homogeneity of variances was tested using Levene's test. Multiple data sets were analysed using Analysis of Variance (ANOVA) and post hoc tests. Least Signifcant Diference was used for variance-aligned data , and the Brown-Forsythe test was used for variance-discrepant data. P < 0.05 was designated as signifcant.

#### **Results**

#### **AGK2 ameliorated pathological damage in ALF mice**

Histological analysis using hematoxylin–eosin (HE) staining revealed that liver lobules in the normal group had a complete structure, clear sinusoids, and no signs of hepatocyte necrosis or infammatory cell infltration (Fig. [1A](#page-3-0)). In contrast, liver samples from the model group exhibited disrupted lobule structures, extensive hepatocyte necrosis, and signifcant infammatory infltration (Fig. [1](#page-3-0)A). However, treatment with AGK2 mitigated these liver tissue damages in the model group (Fig. [1A](#page-3-0)). Serum levels of ALT and AST were signifcantly elevated in the model group compared to the normal group, but these levels were notably decreased in the AGK2 group relative to the model group (Fig. [1B](#page-3-0)-C).

#### **AGK2 afected the autophagy and oxidation in ALF mice**

Fluorescence microscopy results and western blotting showed that compared with the normal group, the protein level of P-PRKAA1, Beclin1 and LC3B-II were signifcantly decreased and protein expression of SIRT2 and P62 was signifcantly increased in model group (Fig. [1D](#page-3-0)-F). As shown in Fig. [1](#page-3-0)G-H, compared with the normal group, levels of MDA and TOS were increased in the model group. However, these levels were reduced in the AGK2 group when compared with the model group.

#### **Efects of diferent TAA concentrations on cell death rate**

To determine an appropriate treatment dosage of TAA for modeling of AML12 cells, the cell death rate of TAA on AML12 cells were measured by flow cytometry. The rate of cell death in TAA-induced AML12 cells showed a concentration-dependent manner. As shown in Fig. [2](#page-4-0)A, the rate of PE-positive cells was 9.35%, 16.09%, 36.24%, 50.91%, 73.98% and 97.36% respectively when treated AML12 cell with TAA which dosage of 0 mM, 30 mM, 60 mM, 90 mM, 120 mM, 150 mM. When treated with 90 mM TAA, the cell death rate of AML12 cell had over 50%. Therefore, we selected the 90 mM TAA in following study.

#### **AGK2 afected the autophagy and oxidation in TAA‑induced AML12 cell**

Fluorescence microscopy results and western blotting showed that compared with the normal group, the protein level of P-PRKAA1, Beclin1 and LC3B-II were signifcantly decreased and protein expression of SIRT2 and P62 was significantly increased in model group (Fig. [2B](#page-4-0)-E). There is no significant difference of the protein level of PRKAA1 among the three groups (Fig. [2B](#page-4-0)-E). As illustrated in Fig. [2](#page-4-0)F-G, compared with the normal group, levels of MDA and TOS were increased in the model group. However, these levels were reduced in the AGK2 group when compared with the model group. The mCherry-GFP-LC3B enabled us to measure the autophagy flux in



<span id="page-3-0"></span>

cells. In the case of non-autophagy, mCherry-GFP-LC3B exists in the cytoplasm in the form of difuse yellow fuorescence; whereas, in the case of autophagy, mCherry-GFP-LC3B aggregates on autophagosome membranes under fuorescence microscopy, and manifests itself in the form of yellow spots. When autophagosomes are fused to lysosomes, they show up as red spots due to partial quenching of GFP fuorescence. Compared with the normal group, The TAA treatment significantly decreased red and yellow point, the decrease of the autophagy fux. Compared with TAA group, the autophagy fux was increased in TAA+AGK2 group (F[ig](#page-4-0). [2H](#page-4-0)-I).

#### **The efect of SIRT2 on P‑PRKAA1 and autophagy in TAA stimulated AML12 cell**

As depicted in Fig. [3](#page-5-0), the OE SIRT2 + TAA group, when compared with the CMV + TAA group, showed a signifcant decrease in the levels of P-PRKAA1, LC3B-II Beclin1, and the autophagy fux, and an increase in the levels of P62, MDA, and TOS. In Fig. [3](#page-5-0)A, the Western blot band of SIRT2 was weak, but the immunofuorescence of SIRT2 was strong (Fig. [3](#page-5-0)C). The strength of the Western blot band intensity are affected by many factors such

4



<span id="page-4-0"></span>Figure 2. (A) The AML12 cell death rate which stimulated by different dosage of TAA was detected by flow cytometry. **(B, C)** The SIRT2 protein and autophagy protein level in AML12 cells were measured by Western blot and quantitatively analyzed. Original blots are presented in Supplementary Figure S2. **(D**, **E)** The fluorescence intensity of AML12 cells SIRT2, PRKAA1 and P-PRKAA by immunofluorescence (scale bars=100 μm). **(F)** Detection of the autolysosomes in AML12 cells by using mCherry-GFP-LC3B observed by confocal microscopy. White boxed regions in the panels are enlarged. (scale bars = 10 μm). **(G)** The mCherrypositive and GFP-negtive LC3-labeled autolysosomes were counted and quantifed in at least 30 randomly picked cells. (**H**, **I**) MDA and TOS levels in AML12 cells detected by kits. Data were expressed as the mean±SD. P values were determined by 2-tailed Student t test. Compared with normal group, \**P* <0.05. Compared with TAA group, #*P*<0.05.



<span id="page-5-0"></span>**Figure 3.** (A, B) The P-PRKAA1 protein and autophagy protein level in AML12 cells were measured by Western blot and quantitatively analyzed. Original blots are presented in Supplementary Figure S3. **(C**, **D**) The fluorescence intensity of AML12 cells SIRT2, PRKAA1 and P-PRKAA by immunofluorescence (scale bars=100 μm). **(E)** Detection of the autolysosomes in AML12 cells by using mCherry-GFP-LC3B observed by confocal microscopy. White boxed regions in the panels are enlarged. (scale bars = 10 μm). (F) The mCherry-positive and GFP-negtive LC3-labeled autolysosomes were counted and quantifed in at least 30 randomly picked cells. (**G**, **H**) MDA and TOS levels in AML12 cells detected by kits. Data were expressed as the mean ± SD. P values were determined by 2-tailed Student t test. Compared with normal group, \*P < 0.05. Compared with  $CMV + TAA$  group,  $#P < 0.05$ .

as exposure time. The trends of the Western blot band as well as the immunofluorescence of SIRT2 was the same in all groups.

Conversely, SIRT2 knockdown in the sh SIRT2 +TAA group upregulated levels of P-PRKAA1, LC3B-II, Beclin1, and downregulated P62, MDA, and TOS levels (Fig. [4A](#page-7-0)-F). Compared to the LKO+TAA group, SIRT2 knockdown signifcantly increased the autophagy fux (Fig. [4G](#page-7-0)-H).

#### **The efect of PRKAA1 on SIRT2 in TAA‑induced AML12 cell**

As shown in Fig. [5,](#page-8-0) compared with CMV+TAA group, the level of P-PRKAA1, LC3B-II, Beclin1 were signifcantly promoted in OE PRKAA1 + TAA group. And the autophagy flux was increased in OE PRKAA1 + TAA group. The level of SIRT2, P62, MDA and TOS were reduced in OE PRKAA1+TAA group. As shown in Fig. [6](#page-9-0), PRKAA1 knockdown could up-regulate SIRT2, P62, MDA and TOS level and down-regulate the P-PRKAA1, LC3B-II, Beclin1 level in sh PRKAA1 + TAA group, compared with LKO + TAA group. Compared with LKO + TAA, PRKAA1 knockdown signifcantly decrease in the autophagy fux (Fig. [6](#page-9-0)G-H).

#### **Discussion**

Our results indicated that TAA caused signifcant disruption of liver structure and function in mice and increased the rate of cell death in AML12 cells in a dose-dependent manner. Recent research increasingly supports the vital role of autophagy in the onset and progression of ALF<sup>[28](#page-11-1),[29](#page-11-2)</sup>. It has been demonstrated that activating autophagy can significantly improve ALF outcomes<sup>[30](#page-11-3),[31](#page-11-4)</sup>.

Autophagy is a principal cellular degradation process where cytoplasmic materials are transported to and broken down in lysosomes<sup>32</sup>. In our study, TAA could decrease the expression of P-PRKAA1 and the autophagy flux. The overexpression of PRKAA1 decreased P62 and SIRT2 protein levels and enhanced P-PRKAA1, Beclin1, and LC3B-II levels in TAA-induced mice and AML12 cells. Previous studies have reported that enhancement of AMPK/glycogen synthase kinase-3β (GSK3β)/Nuclear factor-erythroid 2-related factor 2 (Nrf2) signalling pathway protects against APAP-induced ALF<sup>[33,](#page-11-6)34</sup>.

Sirtuin 2 (SIRT2), a member of the sirtuin family, is characterized by its evolutionarily conserved NAD + -dependent deacetylase activity<sup>35</sup>. The SIRT2 is predominantly found in metabolically active tissues such as the liver, heart, skeletal muscle, and brain<sup>14</sup>. It binds to and deacetylates FoxO3a under oxidative stress conditions, potentially enhancing the expression of FoxO (Forkhead-box class O) target genes such as p27, manganese superoxide dismutase, and Bim<sup>[36](#page-11-9)</sup>. FoxO transcription factors are known to activate mTORC1 (mechanistic target of rapamycin complex 1) by inducing sestrin 3 (Sesn3), which promotes AMPK and inhibits  $mTORC1$ , thus relieving the blockade on autophagy initiation<sup>[37](#page-11-10)</sup>. Previous studies have shown that deletion of SIRT2 reduces the AMPK response to metformin in mice treated with Ang II in the mice model of pathological cardiac hypertrophy[18](#page-10-16). In acute ethanol-exposed macrophages, knockdown of SIRT2 led to increasing LC3 activation<sup>38</sup>. SIRT2 inhibitor NCO-90/14 increases autophagosome accumulation and LC3-II levels in cell lines<sup>[39](#page-11-12)</sup>. In our study, the knockdown of SIRT2 decreased P62 protein levels and enhanced P-PRKAA1, Beclin1, and LC3B-II levels in TAA-induced AML12 cells.

Using both in vivo and in vitro models of ALF induced by TAA, our study explored the efects of SIRT2 inhibition AGK2 and the modulation of PRKAA1 expression through overexpression and knockdown approaches. Histopathological analyses revealed that AGK2 ameliorated liver damage in ALF mice, evidenced by reduced hepatocyte necrosis and infammatory infltration. Kits showed that AGK2 treatment lowered serum ALT and AST levels, indicating reduced hepatic injury. Knockdown of SIRT2 in ALF models led to decreased P62 protein levels, while enhancing P-PRKAA1, Beclin1, and LC3B-II levels, indicating a protective role against autophagy and oxidative stress. Similarly, overexpression of PRKAA1 resulted in decreased SIRT2 levels and reduced markers of oxidative stress, suggesting a regulatory efect of PRKAA1 on SIRT2 and autophagy related pathways. The possible mechanisms were showed as Fig. [7](#page-10-23).

#### **Conclusion**

Based on above results, our data have verifed that SIRT2 plays a signifcant role in the progression of acute liver failure, infuencing key pathways related to autophagy and autophagy. AGK2, as a SIRT2 inhibitor, demonstrated hepatoprotective efects in ALF models by modulating the expression of autophagy-related proteins and reducing oxidative stress markers. Furthermore, our study highlighted the reciprocal regulatory relationship between SIRT2 and PRKAA1/AMPKα, underscoring the complexity of molecular interactions in ALF. Te fndings suggest that targeting the SIRT2-AMPK axis could be a potential therapeutic strategy in ALF management, ofering insights into the molecular mechanisms underlying liver injury and repair. Our study opens up new possibilities for future research exploring targeted interventions for ALF and related liver diseases.

7



<span id="page-7-0"></span>Figure 4. (A, B) The P-PRKAA1 protein and autophagy protein level in AML12 cells were measured by Western blot and quantitatively analyzed. Original blots are presented in Supplementary Figure S4. **(C**, **D**) The fluorescence intensity of AML12 cells SIRT2, PRKAA1 and P-PRKAA by immunofluorescence (scale bars=100 μm). **(E)** Detection of the autolysosomes in AML12 cells by using mCherry-GFP-LC3B observed by confocal microscopy. White boxed regions in the panels are enlarged. (scale bars = 10 μm). **(F)** The mCherry-positive and GFP-negtive LC3-labeled autolysosomes were counted and quantifed in at least 30 randomly picked cells. (**G**, **H**) MDA and TOS levels in AML12 cells detected by kits. Data were expressed as the mean ± SD. P values were determined by 2-tailed Student t test.Compared with normal group, \*P < 0.05. Compared with  $LKO + TAA$  group,  $\#P < 0.05$ .



<span id="page-8-0"></span>Figure 5. (A, B) The SIRT2 protein and autophagy protein level in AML12 cells were measured by Western blot and quantitatively analyzed. Original blots are presented in Supplementary Figure S5. (C, D) The fluorescence intensity of AML12 cells SIRT2, PRKAA1 and P-PRKAA by immunofuorescence (scale bars=100 μm). **(E)** Detection of the autolysosomes in AML12 cells by using mCherry-GFP-LC3B observed by confocal microscopy. White boxed regions in the panels are enlarged. (scale bars = 10 μm). (F) The mCherry-positive and GFP-negtive LC3-labeled autolysosomes were counted and quantifed in at least 30 randomly picked cells. (**G**, **H**) MDA and TOS levels in AML12 cells detected by kits. Data were expressed as the mean±SD. P values were determined by 2-tailed Student t test. Compared with normal group, \*P<0.05. Compared with CMV+TAA group, #P<0.05.



<span id="page-9-0"></span>Figure 6. (A, B) The SIRT2 protein and autophagy protein level in AML12 cells were measured by Western blot and quantitatively analyzed. Original blots are presented in Supplementary Figure S6. (C, D) The fluorescence intensity of AML12 cells SIRT2, PRKAA1 and P-PRKAA by immunofuorescence (scale bars=100 μm). **(E)** Detection of the autolysosomes in AML12 cells by using mCherry-GFP-LC3B observed by confocal microscopy. White boxed regions in the panels are enlarged. (scale bars = 10 μm). (F) The mCherry-positive and GFP-negtive LC3-labeled autolysosomes were counted and quantifed in at least 30 randomly picked cells. (**G**, **H**) MDA and TOS levels in AML12 cells detected by kits. Data were expressed as the mean±SD. P values were determined by 2-tailed Student t test. Compared with normal group, \*P<0.05. Compared with LKO+TAA group, #P<0.05.



<span id="page-10-23"></span>Figure 7. Summary diagram. The SIRT2-AMPK axis regulates autophagy in acute liver failure. TAA: thioacetamide; SIRT2: Sirtuin 2; PRKAA1: protein kinase AMP-activated alpha 1 catalytic subunit; LC3B: Microtubule-Associated Protein 1 Light Chain 3B; ROS: reactive oxygen species.

#### **Data availability**

Data is provided within the manuscript or supplementary information fles.

Received: 23 January 2024; Accepted: 8 July 2024 Published online: 15 July 2024

#### **References**

- <span id="page-10-0"></span>1. Tawley, V. Acute liver injury and failure. *Vet. Clin. North Am. Small Anim. Pract.* **47**, 617–630 (2017).
- <span id="page-10-1"></span>2. Qian, H. *et al.* Autophagy in liver diseases: A review. *Mol. Aspects Med.* **82**, 100973 (2021).
- <span id="page-10-2"></span>3. Ni, H. M. *et al.* Removal of acetaminophen protein adducts by autophagy protects against acetaminophen-induced liver injury in mice. *J. Hepatol.* **65**, 354–362 (2016).
- <span id="page-10-3"></span>4. Li, X. *et al.* FGL2-MCOLN3-autophagy axis-triggered neutrophil extracellular traps exacerbate liver injury in fulminant viral hepatitis. *Cell Mol. Gastroenterol. Hepatol.* **14**, 1077–1101 (2022).
- <span id="page-10-4"></span>5. Zhang, C.-Y. et al. COX-2/sEH dual inhibitor alleviates hepatocyte senescence in NAFLD mice by restoring autophagy through Sirt1/PI3K/AKT/mTOR. *Int. J. Mol. Sci.* **23** (2022).
- <span id="page-10-5"></span>6. Klionsky, D. J. *et al.* Autophagy in major human diseases. *EMBO J.* **40**, e108863 (2021).
- <span id="page-10-6"></span>7. Mihaylova, M. M. & Shaw, R. J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. *Nat. Cell Biol.* **13**, 1016–1023 (2011).
- <span id="page-10-7"></span>8. Kim, J., Kundu, M., Viollet, B. & Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat. Cell Biol.* **13**, 132–141 (2011).
- <span id="page-10-8"></span>9. Wirth, M., Joachim, J. & Tooze, S. A. Autophagosome formation–the role of ULK1 and Beclin1-PI3KC3 complexes in setting the stage. *Semin Cancer Biol.* **23**, 301–309 (2013).
- <span id="page-10-9"></span>10. Chao, X., Wang, H., Jaeschke, H. & Ding, W. X. Role and mechanisms of autophagy in acetaminophen-induced liver injury. *Liver Int.* **38**, 1363–1374 (2018).
- <span id="page-10-10"></span>11. Lin, Z. *et al.* Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice. *J. Hepatol.* **61**(4), 825–831 (2014).
- <span id="page-10-11"></span>12. Obba, S. et al. The PRKAA1/AMPKa1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML. *Autophagy* **11**, 1114–1129 (2015).
- <span id="page-10-12"></span>13. Wu, W. *et al.* TNF-induced necroptosis initiates early autophagy events via RIPK3-dependent AMPK activation, but inhibits late autophagy. *Autophagy* **17**, 3992–4009 (2021).
- <span id="page-10-13"></span>14. Wang, Y., Yang, J., Hong, T., Chen, X. & Cui, L. SIRT2: Controversy and multiple roles in disease and physiology. *Ageing Res. Rev.* **55**, 100961 (2019).
- <span id="page-10-14"></span>15. Fu, G. *et al.* PGAM5 deacetylation mediated by SIRT2 facilitates lipid metabolism and liver cancer proliferation. *Acta Biochim Biophys. Sin. (Shanghai)* **55**, 1370–1379 (2023).
- <span id="page-10-15"></span>16. Zhang, Y. *et al.* SIRT2-mediated deacetylation and deubiquitination of C/EBPbeta prevents ethanol-induced liver injury. *Cell Discov.* **7**, 93 (2021).
- 17. Li, X. *et al.* SIRT2 defciency aggravates diet-induced nonalcoholic fatty liver disease through modulating gut microbiota and metabolites. *Int. J. Mol. Sci.* **24**(10), 8970 (2023).
- <span id="page-10-16"></span>18. Tang, X. *et al.* SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy. *Circulation* **136**, 2051–2067 (2017).
- <span id="page-10-17"></span>19. Liu, N. *et al.* LncRNA LncHrt preserves cardiac metabolic homeostasis and heart function by modulating the LKB1-AMPK signaling pathway. *Basic Res. Cardiol.* **116**, 48 (2021).
- <span id="page-10-18"></span>20. Jung, Y. J., Park, W., Kang, K. P. & Kim, W. SIRT2 is involved in cisplatin-induced acute kidney injury through regulation of mitogen-activated protein kinase phosphatase-1. *Nephrol. Dial. Transpl.* **35**, 1145–1156 (2020).
- <span id="page-10-19"></span>21. Zhang, Q.-Q. *et al.* AGK2 pre-treatment protects against thioacetamide-induced acute liver failure via regulating the MFN2-PERK axis and ferroptosis signaling pathway. *Hepatobil. Pancreat. Dis. Int.* **23**, 43–51 (2024).
- <span id="page-10-20"></span>22. Viswanathan, P., Sharma, Y., Jaber, F.-L., Tchaikovskaya, T. & Gupta, S. Transplanted hepatocytes rescue mice in acetaminopheninduced acute liver failure through paracrine signals for hepatic ATM and STAT3 pathways. *FASEB J.* **35**, e21471 (2021).
- 23. Wang, Y. *et al.* TNF-α/HMGB1 infammation signalling pathway regulates pyroptosis during liver failure and acute kidney injury. *Cell Prolif.* **53**, e12829 (2020).
- 24. Jiao, F.-Z. *et al.* Protective role of AGK2 on thioacetamide-induced acute liver failure in mice. *Life Sci.* **230**, 68–75 (2019).
- <span id="page-10-21"></span>25. Czarnecka, A. M., Hilgier, W. & Zielińska, M. S-Adenosylmethionine defciency and brain accumulation of S-adenosylhomocysteine in thioacetamide-induced acute liver failure. *Nutrients* **12**(7), 2135 (2020).
- <span id="page-10-22"></span>26. Chen, Q. *et al.* Establishing an hTERT-driven immortalized umbilical cord-derived mesenchymal stem cell line and its therapeutic application in mice with liver failure. *J. Tissue Eng* **14**, 20417314231200330 (2023).
- <span id="page-11-0"></span>27. Wang, F. *et al.* Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp. *Acta Pharmacol. Sin.* **38**, 1554–1565 (2017).
- <span id="page-11-1"></span>28. He, Y. *et al.* Mechanisms of fbrosis in acute liver failure. *Liver Int.* **35**, 1877–1885 (2015).
- <span id="page-11-2"></span>29. Qian, H. *et al.* Dual roles of p62/SQSTM1 in the injury and recovery phases of acetaminophen-induced liver injury in mice. *Acta Pharm. Sin. B* **11**, 3791–3805 (2021).
- <span id="page-11-3"></span>30. Chen, Q., Wang, Y., Jiao, F. Z., Shi, C. X. & Gong, Z. J. Histone deacetylase 6 inhibitor ACY1215 ofers a protective efect through the autophagy pathway in acute liver failure. *Life Sci.* **238**, 116976 (2019).
- <span id="page-11-4"></span>31. Ahmedy, O. A., Salem, H. H., Sayed, N. H. & Ibrahim, S. M. Naringenin afords protection against lipopolysaccharide/Dgalactosamine-induced acute liver failure: Role of autophagy. *Arch. Biochem Biophys.* **717**, 109121 (2022).
- <span id="page-11-5"></span>32. Mizushima, N. & Komatsu, M. Autophagy: renovation of cells and tissues. *Cell* **147**, 728–741 (2011).
- <span id="page-11-6"></span>33. Lv, H. *et al.* Corilagin alleviates acetaminophen-induced hepatotoxicity via enhancing the AMPK/GSK3β-Nrf2 signaling pathway. *Cell Commun. Signal* **17**, 2 (2019).
- <span id="page-11-7"></span>34. Zhu, L. *et al.* Xanthohumol protect against acetaminophen-induced hepatotoxicity via Nrf2 activation through the AMPK/Akt/ GSK3β pathway. *Biomed. Pharmacother.* **165**, 115097 (2023).
- <span id="page-11-8"></span>35. Zhu, C. *et al.* Multiple roles of SIRT2 in regulating physiological and pathological signal transduction. *Genet Res. (Camb)* **2022**, 9282484 (2022).
- <span id="page-11-9"></span>36. Wang, F., Nguyen, M., Qin, F. X. & Tong, Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. *Aging Cell* **6**, 505–514 (2007).
- <span id="page-11-10"></span>37. Zhang, J. *et al.* Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways. *Autophagy* **11**, 629–642  $(2015)$
- <span id="page-11-11"></span>38. Gandhirajan, A. *et al.* SIRT2-PFKP interaction dysregulates phagocytosis in macrophages with acute ethanol-exposure. *Front. Immunol.* **13**, 1079962 (2022).
- <span id="page-11-12"></span>39. Kozako, T. *et al.* Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines. *BMC Cancer* **18**, 791 (2018).

#### **Author contributions**

Z.J.G. and Q.Q.Z. designed the research protocol, collected the data of the study, conducted experiment, analyzed the results, also drafed and reviewed the manuscript. J.G., D.M.Z. and C.X.S. analyzed the results and reviewed the manuscript. Y.K.W. and L.W.W. conducted the histopathological and immunofuorescence investigations. All authors have read and approved the manuscript.

#### **Funding**

Tis study was supported by the Natural Science Foundation of China (grant no. 82070609).

#### **Competing interests**

The authors declare no competing interests.

#### **Additional information**

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/](https://doi.org/10.1038/s41598-024-67102-w) [10.1038/s41598-024-67102-w](https://doi.org/10.1038/s41598-024-67102-w).

**Correspondence** and requests for materials should be addressed to Z.G.

**Reprints and permissions information** is available at [www.nature.com/reprints.](www.nature.com/reprints)

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International  $\odot$ License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit<http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024